Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): Results of an international observational registry

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 3, 2012, Pages 283-291

  Alam, Mahboob ^a,b   Bandeali, Salman Jamaluddin ^c   Shahzad, Saima A ^d   Lakkis, Nasser ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d AL NOOR SPECIALIST HOSPITAL   (Saudi Arabia)

Author keywords

atrial fibrillation; rate control; REALISE AF; rhythm control

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT;

CARDIOVASCULAR DISEASE; COMORBIDITY; DEMOGRAPHY; DISEASE REGISTRY; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HUMAN; REVIEW;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; RISK FACTORS;

EID: 84858264047     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.8     Document Type: Review

References (47)

1. Bonhorst D, Mendes M, de Sousa J et al. [Epidemiology of atrial fibrillation]. Rev. Port. Cardiol. 29(7-8), 1207-1217 (2010).
2. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114(7), e257-e354 (2006). (Pubitemid 44252297)
3. Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol. Clin. 27(1), 13-24 (2009).
4. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol. 82(8A), 2N-9N (1998). (Pubitemid 28507114)
5. Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110(9), 1042-1046 (2004). (Pubitemid 39319000)
6. Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin. Cardiol. 31(2), 55-62 (2008). (Pubitemid 351320498)
7. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am. J. Cardiol. 74(3), 236-241 (1994). (Pubitemid 24239044)
8. Heeringa J, Van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart J. 27(8), 949-953 (2006).
9. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347(23), 1825-1833 (2002). (Pubitemid 35417773)
10. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347(23), 1834-1840 (2002). (Pubitemid 35417774)
11. Van Gelder IC, Crijns HJ, Tieleman RG et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch. Intern. Med. 156(22), 2585-2592 (1996). (Pubitemid 26404796)
12. Blackshear JL, Safford RE. AFFIRM and RACE trials: implications for the management of atrial fibrillation. Card. Electrophysiol. Rev. 7(4), 366-369 (2003).
13. Groenveld HF, Crijns HJ, Rienstra M, Van den Berg MP, Van Veldhuisen DJ, Van Gelder IC. Does intensity of rate control influence outcome in persistent atrial fibrillation? Data of the RACE study. Am. Heart J. 158(5), 785-791 (2009).
14. Groenveld HF, Crijns HJ, Van den Berg MP et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J. Am. Coll. Cardiol. 58(17), 1795-1803 (2011).
15. Van Gelder IC, Groenveld HF, Crijns HJ et al. Lenient versus strict rate control in patients with atrial fibrillation. N. Engl. J. Med. 362(15), 1363-1373 (2010).
16. Bijsterveld N. [No improvement in prognosis by intensive rate control in atrial fibrillation]. Ned Tijdschr Geneeskd. 154(9), 425 (2010).
17. Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med. 358(25), 2667-2677 (2008). (Pubitemid 351860859)
18. Caldeira D, David C, Sampaio C. Rate vs rhythm control in patients with atrial fibrillation and heart failure: a systematic review and meta-analysis of randomised controlled trials. Eur. J. Intern. Med. 22(5), 448-455 (2011).
19. Kumana CR, Cheung BM, Cheung GT, Ovedal T, Pederson B, Lauder IJ. Rhythm vs. rate control of atrial fibrillation meta-analysed by number needed to treat. Br. J. Clin. Pharmacol. 60(4), 347-354 (2005). (Pubitemid 41428465)
20. Testa L, Biondi-Zoccai GG, Dello Russo A, Bellocci F, Andreotti F, Crea F. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur. Heart J. 26(19), 2000-2006 (2005). (Pubitemid 41439642)
21. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med. Clin. North Am. 92(1), 17-40 (2003). (Pubitemid 350182405)
22. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb. Res. 118(3), 321-333 (2006). (Pubitemid 44067199)
23. Steg PG, Alam S, Chiang CE et al. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the REALISE-AF cross-sectional international registry. Heart 98(3), 195-201 (2012).
24. Kirchhof P, Auricchio A, Bax J et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur. Heart J. 28(22), 2803-2817 (2007).
25. Nieuwlaat R, Capucci A, Camm AJ et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur. Heart J. 26(22), 2422-2434 (2005 (Pubitemid 41552972)
26. Singh SN, Tang XC, Singh BN et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a veterans affairs cooperative studies program substudy. J. Am. Coll. Cardiol. 48(4), 721-730 (2006). (Pubitemid 44175705)
27. Gronefeld GC, Lilienthal J, Kuck KH, Hohnloser SH. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur. Heart J. 24(15), 1430-1436 (2003). (Pubitemid 36961833)
28. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356(9244), 1789-1794 (2000).
29. Carlsson J, Miketic S, Windeler J et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J. Am. Coll. Cardiol. 41(10), 1690-1696 (2003). (Pubitemid 36584236)
30. Opolski G, Torbicki A, Kosior DA et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest 126(2), 476-486 (2004). (Pubitemid 39093433)
31. Cordina J, Mead G. Pharmacological cardioversion for atrial fibrillation and flutter. Cochrane Database Syst. Rev. 2, CD003713 (2005).
32. Okcun B, Yigit Z, Arat A, Kucukoglu SM. Comparison of rate and rhythm control in patients with atrial fibrillation and nonischemic heart failure. Jpn Heart J. 45(4), 591-601 (2004). (Pubitemid 41521902)
33. Singer DE. Anticoagulation to prevent stroke in atrial fibrillation and its implications for managed care. Am. J. Cardiol. 81(5A), 35C-40C (1998). (Pubitemid 28158851)
34. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22), 2864-2870 (2001). (Pubitemid 32537350)
35. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343(8899), 687-691 (1994).
36. Connolly SJ, Pogue J, Hart RG et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. 360(20), 2066-2078 (2009).
37. Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367(9526), 1903-1912 (2006).
38. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139-1151 (2009).
39. Wann LS, Curtis AB, January CT et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123(1), 104-123 (2011).
40. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J. Cardiovasc. Electrophysiol. 21(6), 597-605 (2010).
41. Turpie AG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373(9676), 1673-1680 (2009).
42. Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632), 31-39 (2008).
43. Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, Phase II trial. Lancet 374(9683), 29-38 (2009).
44. ROCKET-AF Study Investigators. Rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am. Heart J. 159(3), 340-347, e341 (2010).
45. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883-891 (2011).
46. Lopes RD, Alexander JH, Al-Khatib SM et al. Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am. Heart J. 159(3), 331-339 (2010).
47. Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374(9689), 534-542 (2009).